Cosentyx (secukinumab) is a medication used to treat a variety of conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug known as a monoclonal antibody, which works by targeting and blocking a specific protein in the body (interleukin-17A) that is believed to play a role in inflammation [1].

According to the manufacturer's prescribing information, there are limited data on the effects of Cosentyx on the immune response to vaccines [1]. However, it is generally recommended that live vaccines be avoided in patients receiving immunosuppressive therapy, such as Cosentyx [1]. This is because these types of vaccines, which contain live, weakened forms of a virus or bacteria, can cause infection in individuals with weakened immune systems [2].

It is important to note that the immune response to non-live vaccines (also known as inactivated or killed vaccines) may also be affected by immunosuppressive therapy [2]. However, the manufacturer states that the overall risk of infection following administration of these types of vaccines in patients receiving Cosentyx is unknown [1].

In summary, it is not clear whether Cosentyx will alter a person's immune response to vaccines. However, it is generally recommended that live vaccines be avoided in patients receiving this medication. It is always best to consult with a healthcare provider before receiving any vaccinations while taking Cosentyx.

Sources:

1. Cosentyx (secukinumab) [prescribing information]. Novartis Pharmaceuticals Corporation; 2021. Available at: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
2. Centers for Disease Control and Prevention. Vaccination of persons with altered immunocompetence. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Washington, DC: Public Health Foundation; 2021:225-234. Available at: <https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf>.
3. DrugPatentWatch. Secukinumab. Available at: <https://www.drugpatentwatch.com/drugs/secukinumab>.